Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $22.10 USD
Change Today -0.40 / -1.78%
Volume 993.0K
HALO On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

halozyme therapeutics inc (HALO) Snapshot

Open
$22.44
Previous Close
$22.50
Day High
$22.47
Day Low
$21.63
52 Week High
07/1/15 - $23.16
52 Week Low
12/16/14 - $7.51
Market Cap
2.8B
Average Volume 10 Days
1.5M
EPS TTM
$-0.45
Shares Outstanding
127.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HALOZYME THERAPEUTICS INC (HALO)

halozyme therapeutics inc (HALO) Related Businessweek News

No Related Businessweek News Found

halozyme therapeutics inc (HALO) Details

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter abnormal tissue structures for clinical benefit. The company’s products are based on the Enhanze technology, a patented human recombinant hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. The company is also developing PEGPH20, a new molecular entity that is in Phase II clinical trials for the treatment of metastatic pancreatic cancer, as well as in Phase I clinical trial for the treatment of non-small cell lung cancer; and Hylenex recombinant for use as pre-treatment in patients with type 1 diabetes using pumps and recombinant human cathepsin L (HTI-501) for the treatment of cellulite. It has collaborative partnerships with F. Hoffmann-La Roche, Ltd., Hoffmann-La Roche, Inc., Baxter Healthcare Corporation, Pfizer Inc., and Janssen Biotech, Inc. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

153 Employees
Last Reported Date: 03/2/15
Founded in 1998

halozyme therapeutics inc (HALO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $1.6M
Compensation as of Fiscal Year 2014.

halozyme therapeutics inc (HALO) Key Developments

Halozyme Therapeutics, Inc. Announces Executive Changes Effective June 15, 2015

Halozyme Therapeutics, Inc. announced its chief financial officer David Ramsay will retire this summer, and named biotech veteran Laurie Stelzer as his successor. Stelzer will assume CFO duties on June 15, 2015 and will work with Ramsay through a transition period. Most recently at Shire, Stelzer served as senior vice president of Finance for R&D, Technical Operations and Business Development, and was previously Division CFO for Regenerative Medicine. Before Shire, she spent 15 years at Amgen, in senior leadership roles in finance and business development with responsibilities including the U.S., Canada and International Markets, ultimately serving as the company's acting treasurer. In this role, she led a leveraged recapitalization that included $10 billion in bond offerings and the corresponding expanded share buyback program, which contributed to an increase in shareholder value.

Halozyme Enters into Global Collaboration and Licensing Agreement with AbbVie

Halozyme Therapeutics, Inc. announced a global collaboration and license agreement with AbbVie to develop and commercialize products combining proprietary AbbVie compounds with Halozyme's ENHANZE™ platform. Under the terms of the agreement, Halozyme will receive an initial $23 million payment, followed by milestone payments totaling approximately $130 million for each of up to nine collaboration targets. These payments are subject to AbbVie's achievement of specified development, regulatory and sales-based milestones. In addition, AbbVie will pay Halozyme tiered royalties if products under the collaboration are commercialized.

Halozyme Therapeutics, Inc. Announces Interim Findings from the Ongoing Phase 2 Clinical Study of Investigational Drug PEGPH20

Halozyme Therapeutics, Inc. announced interim findings from the ongoing phase 2 clinical study of its investigational new drug PEGPH20 for the potential treatment of patients with metastatic pancreatic cancer. The trial included 135 treated patients in stage 1, of whom a total of 44 patients - 23 receiving PEGPH20 in combination with ABRAXANE® and gemcitabine (PAG treatment arm) and 21 receiving ABRAXANE and gemcitabine alone (AG treatment arm) - had available biopsies that were determined in a retrospective analysis to have high levels of hyaluronan (HA). PEGPH20 targets HA to help improve cancer therapy access to tumor cells. Results reported include: A more than doubling of median progression-free survival of 9.2 months versus 4.3 months in high HA patients treated with PAG vs. AG (hazard ratio of 0.39; p-value of 0.05); A more than doubling of overall response rate of 52% against 24% (p-value of 0.038) and a duration of response of 8.1 months compared to 3.7 months in high HA patients treated with PAG versus AG; In the 30 high HA patients (15 PAG treatment arm versus 15 AG treatment arm) who were evaluated for response prior to the April 2014 clinical hold and subsequent PEGPH20 treatment discontinuation, the overall response rate was 73% against 27% (p-value of 0.01), respectively, consistent with findings presented in January; A trend toward improvement in median overall survival of 12 months compared to 9 months in high HA patients treated with PAG versus AG (hazard ratio of 0.62) despite discontinuation of PEGPH20 in more than half of the PAG-treated patients at the time of the clinical hold in April 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HALO:US $22.10 USD -0.40

HALO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amphastar Pharmaceuticals Inc $17.24 USD -0.26
Valeant Pharmaceuticals International Inc C$287.80 CAD +1.10
View Industry Companies
 

Industry Analysis

HALO

Industry Average

Valuation HALO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 33.8x
Price/Book 73.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 32.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HALOZYME THERAPEUTICS INC, please visit www.halozyme.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.